Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2022-01-14 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
第三届监事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company regarding the approval of a proposal to use idle raised funds temporarily to supplement working capital. It includes details about the meeting, attendance, voting results, and compliance with relevant laws and regulations. It references another announcement about the use of idle raised funds but does not contain financial statements or detailed financial data itself. The document is an official announcement of a board/management decision rather than a full report or financial statement. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on a board resolution, not a full report or audit.
2022-01-14 Chinese
第三届董事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 27th meeting of the third board of directors of Betta Pharmaceuticals Co., Ltd. It details the meeting's convening, attendance, and the approval of specific proposals such as the use of idle raised funds to supplement working capital and the proposal to submit changes in registered capital and amendments to the company's articles of association to the shareholders' meeting. The document is an official disclosure of board decisions rather than a full management report or financial statement. It does not contain financial data or detailed analysis but rather announces board meeting outcomes. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors.
2022-01-14 Chinese
中信证券股份有限公司关于贝达药业股份有限公司增加2021年日常关联交易预计额度的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the increase in the 2021 daily related-party transaction estimated quota for 贝达药业股份有限公司. It includes descriptions of board meetings, independent director opinions, transaction details, and compliance with regulatory rules. The document is not a financial report itself but a verification or audit opinion related to a specific corporate governance matter concerning related-party transactions. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles or internal regulatory checks excluding full annual reports. The document length is under 5,000 characters, but it is substantive and not merely an announcement of a report publication, so it is not RPA or RNS. Therefore, the best classification is AR with high confidence. FY 2021
2022-01-06 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2022年日常关联交易预计事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed special verification opinion by CITIC Securities regarding the 2022 expected daily related party transactions of Betta Pharmaceuticals Co., Ltd. It includes extensive descriptions of related parties, transaction amounts, pricing principles, independent directors' opinions, and compliance with regulatory requirements. The document is not a full annual or interim financial report but a specialized audit or verification report focused on related party transactions. It is not a simple announcement or certification but contains substantive analysis and opinions. Therefore, it fits best under the category of Audit Report / Information (AR). The document length (7086 characters) supports it being a full report rather than a brief announcement. FY 2022
2022-01-06 Chinese
关于2022年日常关联交易预计的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's expected related party transactions for the year 2022. It includes descriptions of the related parties, transaction amounts, pricing principles, and independent directors' opinions. The document is an announcement of anticipated related party transactions, which is a type of capital or financing update related to the company's operational dealings with affiliates. It is not a full financial report, audit, or earnings release, nor is it a regulatory filing or a simple report publication announcement. The content fits best under Capital/Financing Update (CAP) as it updates on expected related party transactions and their financial impact.
2021-12-29 Chinese
第三届监事会第二十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 贝达药业股份有限公司 regarding approval of daily related-party transaction budgets for 2021 and 2022. It includes meeting details, voting results, and references to related announcements. The document is short (1257 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, audit report, or earnings release. It is a formal meeting resolution announcement related to corporate governance and related-party transactions. This fits best under Regulatory Filings (RNS) as it is a regulatory announcement of meeting resolutions and related-party transaction approvals, not a full report or presentation.
2021-12-29 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.